Literature DB >> 23390031

Direct comparison of [(18) F]MH.MZ and [(18) F] altanserin for 5-HT2A receptor imaging with PET.

Hanne D Hansen1, Anders Ettrup, Matthias M Herth, Agnete Dyssegaard, Cecilia Ratner, Nic Gillings, Gitte M Knudsen.   

Abstract

Imaging the cerebral serotonin 2A (5-HT2A ) receptors with positron emission tomography (PET) has been carried out in humans with [(11) C]MDL 100907 and [(18) F]altanserin. Recently, the MDL 100907 analogue [(18) F]MH.MZ was developed combining the selectivity profile of MDL 100907 and the favourable radiophysical properties of fluorine-18. Here, we present a direct comparison of [(18) F]altanserin and [(18) F]MH.MZ. 5-HT2A receptor binding in pig cortex and cerebellum was investigated by autoradiography with [(3) H]MDL 100907, [(18) F]MH.MZ, and [(18) F]altanserin. [(18) F]MH.MZ and [(18) F]altanserin were investigated in Danish Landrace pigs by brain PET scanning at baseline and after i.v. administration of blocking doses of ketanserin. Full arterial input function and high performance liquid chromatography (HPLC) analysis allowed for tissue-compartment kinetic modeling of PET data. In vitro autoradiography showed high binding in cortical regions with both [(18) F]MH.MZ and [(18) F]altanserin. Significant 5-HT2A receptor binding was also found in the pig cerebellum, thus making this region unsuitable as a reference region for in vivo data analysis in this species. The cortical binding of [(18) F]MH.MZ and [(18) F]altanserin was blocked by ketanserin supporting that both radioligands bind to 5-HT2A receptors in the pig brain. In the HPLC analysis of pig plasma, [(18) F]MH.MZ displayed a fast and reproducible metabolism resulting in hydrophilic radiometabolites only whereas the metabolic profile of [(18) F]altanserin as expected showed lipophilic radiometabolites. Due to the slow kinetics of [(18) F]MH.MZ in high-binding regions in vivo, we suggest that [(18) F]MH.MZ will be an appropriate tracer for low binding regions where kinetics will be faster, whereas [(18) F]altanserin is a suitable tracer for high-binding regions.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23390031     DOI: 10.1002/syn.21643

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  8 in total

Review 1.  PET tracers for serotonin receptors and their applications.

Authors:  J S Dileep Kumar; J John Mann
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2014

2.  Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain.

Authors:  Vasko Kramer; Agnete Dyssegaard; Jonathan Flores; Cristian Soza-Ried; Frank Rösch; Gitte Moos Knudsen; Horacio Amaral; Matthias M Herth
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-12       Impact factor: 9.236

3.  Serotonin 2A receptor agonist binding in the human brain with [¹¹C]Cimbi-36.

Authors:  Anders Ettrup; Sophie da Cunha-Bang; Brenda McMahon; Szabolcs Lehel; Agnete Dyssegaard; Anine W Skibsted; Louise M Jørgensen; Martin Hansen; Anders O Baandrup; Søren Bache; Claus Svarer; Jesper L Kristensen; Nic Gillings; Jacob Madsen; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2014-04-30       Impact factor: 6.200

4.  NRM 2021 Abstract Booklet.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2021-12       Impact factor: 6.960

5.  Automated synthesis of (R)-[18 F]MH.MZ on the iPhase Flexlab reaction platform.

Authors:  Adam J Rosenberg; Yiu-Yin Cheung; Fei Liu; Todd E Peterson; James Silverman; Ciaran M Considine; Daniel O Claassen
Journal:  J Labelled Comp Radiopharm       Date:  2022-05-06       Impact factor: 1.949

Review 6.  Radiotracers for the Central Serotoninergic System.

Authors:  Reynald Mangeant; Emmanuelle Dubost; Thomas Cailly; Valérie Collot
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-03

7.  First-in-Human Study of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET for Integrin αvβ3 Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging Ability.

Authors:  Malene Martini Clausen; Esben Andreas Carlsen; Camilla Christensen; Jacob Madsen; Malene Brandt-Larsen; Thomas Levin Klausen; Søren Holm; Annika Loft; Anne Kiil Berthelsen; Niels Kroman; Ulrich Knigge; Andreas Kjaer
Journal:  Diagnostics (Basel)       Date:  2022-03-30

8.  First-in-human uPAR PET: Imaging of Cancer Aggressiveness.

Authors:  Morten Persson; Dorthe Skovgaard; Malene Brandt-Larsen; Camilla Christensen; Jacob Madsen; Carsten H Nielsen; Tine Thurison; Thomas Levin Klausen; Søren Holm; Annika Loft; Anne Kiil Berthelsen; Michael Ploug; Helle Pappot; Klaus Brasso; Niels Kroman; Liselotte Højgaard; Andreas Kjaer
Journal:  Theranostics       Date:  2015-09-13       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.